New insights in the multiple roles of bile acids and their signaling pathways in metabolic control

Current Opinion in Lipidology

Volumn 29, Issue 3, 2018, Pages 194-202

  De Boer, Jan Freark ^a   Bloks, Vincent W ^a   Verkade, Esther ^a   Heiner Fokkema, M Rebecca ^a   Kuipers, Folkert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

bile acids; cytochrome P450; farnesoid X receptor; takeda G receptor 5

Indexed keywords

25 HYDROXYCHOLESTEROL; BILE ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; HORMONE RECEPTOR; OXYSTEROL; TAKEDA G RECEPTOR 5; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

AGING; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILIARY EXCRETION; ENTEROHEPATIC CIRCULATION; HOMEOSTASIS; HUMAN; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

AGING; ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; HUMANS; MICE; MICE, TRANSGENIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85046695934     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000508     Document Type: Review

References (65)

1. Chiang JY, Pathak P, Liu H, et al. Intestinal farnesoid X receptor and takeda G protein couple receptor 5 signaling in metabolic regulation. Dig Dis 2017; 35:241-245.
2. Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res 2017; 1:3-9.
3. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-191.
4. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap-bile acids in metabolic control. Nat Rev Endocrinol 2014; 10:488-498.
5. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing te levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235.
6. Hu X, Bonde Y, Eggertsen G, Rudling M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 2014; 275:27-38.
7. Hofmann AF, Hagey LR. Hey discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 2014; 55:1553-1595.
8. Trauner M, Fuchs CD, Halibasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 2017; 65:1393-1404.
9. Stellaard F, Brufau G, Boverhof R, et al. Developments in bile acid kinetic measurements using (13)C and (2)H: 10(5) times improved sensitivity during the last 40 years. Isotopes Environ Health Stud 2009; 45:275-288.
10. Stellaard F, Sackmann M, Berr F, Paumgartner G. Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling. Biomed Environ Mass Spectrom 1987; 14:609-611.
11. Neese RA, Faix D, Kletke C, et al. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am J Physiol 1993; 264:E136-E147.
12. Faix D, Neese RA, Kletke C, et al. Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans. J Lipid Res 1993; 34:2063-2075.
13. Charach G, Argov O, Geiger K, et al. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Therap Adv Gastroenterol 2018; 11:1-11.
14. Verkade HJ, Vonk RJ, Kuipers F. New insights into the mechanism of bile acidinduced biliary lipid secretion. Hepatology 1995; 21:1174-1189.
15. Voshol PJ, Schwarz M, Rigotti A, et al. Down-regulation of intestinal scavenger receptor class B, type I (SR-BI) expression under conditions of deficient bile delivery to the intestine. Biochem J 2001; 356:317-325.
16. Wang DQ, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol 2003; 285: G494-G502.
17. Bosner MS, Lange LG, Stenson WF, et al. Percentage cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999; 40:302-308.
18. de Boer JF, Schonewille M, Boesjes M, et al. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology 2017; 152:1126-1138.
19. Fiamoncini J, Yiorkas AM, Gedrich K, et al. Determinants of postprandial plasma bile acid kinetics in human volunteers. Am J Physiol Gastrointest Liver Physiol 2017; 313:G300-G312.
20. Legry V, Francque S, Haas JT, et al. Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects. J Clin Endocrinol Metab 2017; 102:3783-3794.
21. Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatophepatitis is associated with specific changes in circulating bile acids. Hepatology 2018; 67:534-548.
22. Spinelli V, Lalloyer F, Baud G, et al. Influence of Roux-en-Y bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes (Lond) 2016; 40:1260-1267.
23. Albaugh VL, Flyn CR, Cai S, et al. Early increases in bile acids post Roux-en-Y gastric bypass are driven by insulin-sensitizing secondary bile acids. J Clin Endocrinol Metab 2015; 100:E1225-E1233.
24. Burstein MT, Kyryakov P, Beach A, et al. Lithocholic acid extends longevity of chronologically aging yeast only if added at certain critical periods of their lifespan. Cell Cycle 2012; 11:3443-3462.
25. Mahanti P, Bose N, Bethke A, et al. Comparative metabolomics reveals endogenous ligands of DAF-12, a nuclear hormone receptor, regulating C. elegans development and lifespan. Cell Metab 2014; 19:73-83.
26. Gems D. Long-lived dwarf mice: are bile acids a longevity signal? Aging Cell 2007; 6:421-423.
27. Cheng S, Larson MG, McCabe EL, et al. Distinct metabolomic signatures are associated with longevity in humans. Nat Commun 2015; 6:6791.
28. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-1464.
29. Kang DJ, Hylemon PB, Gillevet PM, et al. Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. Hepatol Commun 2017; 1:61-70.
30. Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun 2017; 8:1785.
31. Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol 2004; 7:315-334.
32. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110:109-117.
33. Ishibashi S, Schwarz M, Frykman PK, et al. Disruption of cholesterol 7alphahydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation. J Biol Chem 1996; 271:18017-18023.
34. Schwarz M, Lund EG, Setchell KD, et al. Disruption of cholesterol 7alphahydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J Biol Chem 1996; 271:18024-18031.
35. Erickson SK, Lear SR, Deane S, et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J Lipid Res 2003; 44:1001-1009.
36. Liu H, Pathak P, Boehme S, Chiang JY. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. J Lipid Res 2016; 57:1831-1844.
37. Donepudi AC, Ferrell JM, Boehme S, et al. Deficiency of cholesterol 7αhydroxylase in bile acid synthesis exacerbates alcohol-induced liver injury in mice. Hepatol Commun 2017; 2:99-112.
38. Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis 2017; 40:771-781.
39. Gong J-Y, Setchell KDR, Zhao J, et al. Severe neonatal cholestasis in cerebrotendinous xanthomatosis: genetics, immunostaining, mass spectrometry. J Pediatr Gastroenterol Nutr 2017; 65:561-568.
40. Dubrac S, Lear SR, Ananthanarayanan M, et al. Role of CYP27A in cholesterol and bile acid metabolism. J Lipid Res 2005; 46:76-85.
41. 5 bile acids in serum and urine: not necessarily primary oxysterol 7α hydroxylase deficiency. Clin Chim Acta 2012; 413:1700-1704.
42. Lorbek G, Lewinska M, Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids - from mouse models to human diseases. FEBS J 2012; 279:1516-1533.
43. Worthmann A, John C, Rühlemann MC, et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med 2017; 23:839-849.
44. Broeders EP, Nascimento EB, Havekes B, et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 2015; 22:418-426.
45. Brufau G, Bahr MJ, Staels B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab 2010; 7:73.
46. Takahashi S, Fukami T, Masuo Y, et al. Cyp2c70 is responsible for the species differences in bile acid metabolism between mice and humans. J Lipid Res 2016; 57:2130-2137.
47. [No authors listed]. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
48. Hansen M, Sonne DP, Mikkelsen KH, et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with metaanalysis of randomized controlled trials. J Diabetes Complications 2017; 31:918-927.
49. Hegade VS, Jones DE, Hirschfield GM. Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis. Dig Dis 2017; 35:267-274.
50. Harach T, Pols TW, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012; 2:430.
51. Duboc H, Taché Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014; 46:302-312.
52. Eggink HM, Tambyrajah LL, van den Berg R, et al. Chronic infusion of taurolithocholate into the brain increases fat oxidation in mice. J Endocrinol 2018; 236:85-97.
53. Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 2012; 1821:1443-1452.
54. Pols TW, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011; 54:1263-1272.
55. Biagioli M, Carino A, Cipriani S, et al. The Bile Acid Receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J Immunol 2017; 199:718-733.
56. Hao H, Cao L, Jiang C, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab 2017; 25:856-867.e5.
57. Guo C, Xie S, Chi Z, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 2016; 45:802-816.
58. Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorg Med Chem Lett 2009; 19:4733-4739.
59. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385:956-965.
60. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145:574-582.e1.
61. Hambruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 2012; 343:556-567.
62. Tully DC, Rucker PV, Chianelli D, et al. Discovery of tropifexor (LJN452), a highly potent nonbile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem 2017; 60:9960-9973.
63. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14:747-757.
64. Velazquez-Villegas LA, Perino A, Lemos V, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat Commun 2018; 9:245.
65. Jadhav K, Xu Y, Xu Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab 2018; 9:131-140.